OncoMatch/Clinical Trials/NCT05488548
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
Is NCT05488548 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies EP31670 for castrate resistant prostate cancer.
Treatment: EP31670 — A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Acute Myeloid Leukemia
Myeloproliferative Neoplasm
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: antiandrogen
Relapse or refractory castration-resistant prostate cancer (CRPC) following at least one anti-androgen regimen
Must have received: taxane (docetaxel)
Relapse or refractory castration-resistant prostate cancer (CRPC) following ... a docetaxel-containing regimen
Must have received: hypomethylating agent
relapsed or refractory CMML following at least 4 cycles of hypomethylating agent-containing regimen
Must have received: hydroxyurea (hydroxyurea)
relapsed or refractory CMML following ... hydroxyurea unless demonstration of progression or intolerance
Must have received: JAK inhibitor
advanced MF (intermediate or high-risk) following at least one JAK inhibitor-containing regimen
Lab requirements
Blood counts
Hemoglobin ≥ 9.0 g/dL (Part 1); ANC ≥ 1,500/dL (Part 1); Platelet count ≥100,000/μL (Part 1) or ≥75,000/μL (Part 3)
Kidney function
Creatinine clearance (CLcr) ≥ 60 mL/min
Liver function
total bilirubin ≤ 1.5 x ULN; ALT or AST ≤ 2.5 x ULN or ≤ 5 x ULN in patients with liver metastases
Cardiac function
Internal normalized ratio for prothrombin time (INR) ≤ 1.2 in patients not receiving chronic anticoagulation; Corrected QT interval <470 msec
Adequate bone marrow function: Hemoglobin ≥ 9.0 g/dL (Part 1); ANC ≥ 1,500/dL (Part 1); Platelet count ≥100,000/μL (Part 1) or ≥75,000/μL (Part 3). Adequate renal function: Creatinine clearance (CLcr) ≥ 60 mL/min. Adequate liver function: total bilirubin ≤ 1.5 x ULN; ALT or AST ≤ 2.5 x ULN or ≤ 5 x ULN in patients with liver metastases. Internal normalized ratio for prothrombin time (INR) ≤ 1.2 in patients not receiving chronic anticoagulation. Corrected QT interval <470 msec.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Arizona · Phoenix, Arizona
- Mayo Clinic Florida · Jacksonville, Florida
- Dana Farber Cancer Institute · Boston, Massachusetts
- Mayo Clinic Rochester · Rochester, Minnesota
- The University of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05488548 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received antiandrogen and taxane.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages